Login to Your Account

Vaccibody's HPV approach reaps $25M via placement

By Randy Osborne
Staff Writer

Thursday, December 15, 2016

Taking aim at human papillomavirus (HPV)16-induced cervical lesions in a phase I/IIa study with its therapeutic cancer vaccine, Norway-based Vaccibody AS added NOK220 million (US$25 million) to the coffers in a private placement, selling 880,000 shares at NOK250 each.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription